RenovaCare, Inc. (OTCMKTS:RCAR) Files An 8-K Entry into a Material Definitive Agreement

RenovaCare, Inc. (OTCMKTS:RCAR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement

On August 15, 2019, RenovaCare, Inc. (the “Company”) and Dr. Robin Robinson executed an Executive Services Consulting Agreement (“Agreement”), effective August 15, 2019, a form of which is attached as Exhibit 10.1 hereto. to this Agreement, Dr. Robinson will serve as the Company’s Vice President of Scientific Affairs, for which he will be compensated $5,000 per month. At the discretion of the Board, he may also be eligible for equity stock options or equity awards to the Company\’s equity incentive compensation plans in effect from time to time. The term of the Agreement commences on the effective date and shall terminate following written notice by either party or by mutual written consent as provided for in the Agreement.

The summary of the terms of the Agreement included in this Current Report on Form 8-K (this “Report”) does not purport to be complete and is qualified in its entirety by reference to the Agreement as attached as Exhibit 10.1 and is incorporated by reference herein; capitalized but undefined terms used in this Report have the meaning ascribed to such term in the Agreement.

For the eight years to April 2016, Dr. Robinson was the Director of the Biomedical Advanced Research and Development Authority at the U.S. Department of Health and Human Services. From May 2016 to the present, Dr. Robinson has provided consultation services to multiple multi-national and U.S.-based vaccine, pharmaceutical, venture capital, and scientific consulting companies. Additionally, he has served as an acting chief executive officer of U.S.-based start-up vaccine company and served as a senior scientist to advise on the creation of a new company focused on the development of stem cell therapies.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

The following exhibit is filed herewith:

10.1 Executive Services Consulting Agreement, dated August 15, 2019, and effective August 15, 2019, by and between RenovaCare, Inc. and Robin Robinson.


RenovaCare, Inc. Exhibit
EX-10.1 2 exh_101.htm EXHIBIT 10.1 Exhibit 10.1   Renovacare,…
To view the full exhibit click here

Story continues below

About RenovaCare, Inc. (OTCMKTS:RCAR)

RenovaCare, Inc., formerly Janus Resources, Inc., is a biotechnology company. The Company is focused on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The Company’s initial products under development target skin. The Company, through RenovaCare Sciences Corp., offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). It is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Its technology, the CellMist System, uses SkinGun to spray a liquid suspension of a patient’s stem cells, the CellMist Solution, onto wounds. The CellMist System harvests a patient’s stem cells from a small area of skin and suspends them in the water-based CellMist Solution.

An ad to help with our costs